Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a multi-site, single arm phase II trial of cabozantinib for IMDC all-risk frontline
metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not
previously been treated with cabozantinib.